Cochrane · systematic review · CD013487
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta‐analysis
Piechotta, V, Jakob, T, Langer, P, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
0
No studies
3
Included studies
NR
No studies 3 · 75%Ungraded 1 · 25%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings
Population: newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Polyneuropathies | no estimate extracted | NR | No studies |
Serious adverse events | no estimate extracted | NR | No studies |
Withdrawals due to adverse events | no estimate extracted | 82 participants | Ungraded |
Quality of life | no estimate extracted | NR | No studies |